Journals / Yeni Tıp Dergisi / 2010 / Cilt: 27 - Sayı: 4

Male breast cancer

Erkek meme kanseri

Pages
202–207
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Globally, older age, larger tumor size, axillary lymph node metastasis, advanced stage, higher grade, and hormone receptor negativity are associated with poor prognosis in MBC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Male breast cancer (MBC) is a rare disease accounting for less than 1% of all cancers in men and comprises about 1% of all breast cancers.
📊
Key Findings & Data:Because of its rarity, there have been no prospective randomized trials and most of data depends on small single institution retrospective studies or female breast cancer (FBC) trials.
💡
Conclusion & Impact:Globally, older age, larger tumor size, axillary lymph node metastasis, advanced stage, higher grade, and hormone receptor negativity are associated with poor prognosis in MBC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Male breast cancer (MBC) is a rare disease accounting for less than 1% of all cancers in men and comprises about 1% of all breast cancers. Because of its rarity, there have been no prospective randomized trials and most of data depends on small single institution retrospective studies or female breast cancer (FBC) trials. This article presents an overview of MBC with emphasis on incidence, etiology, clinical features, diagnosis, treatment, pathology, survival, prognostic factors. MBC and FBC contrast in the age at diagnosis, tumor stage, histological types, molecular markers, expression of steroid hormone receptor. Modified radical mastectomy remains the standard treatment, adjuvant radiotherapy is often performed and tamoxifen is used. Globally, older age, larger tumor size, axillary lymph node metastasis, advanced stage, higher grade, and hormone receptor negativity are associated with poor prognosis in MBC.

Özet

Erkek meme kanseri (EMK) nadir bir hastalıktır. Erkek-lerdeki tüm kanserlerin %1’den daha azı ve tüm meme kanserlerinin yaklaşık %1’ini oluşturur. Nadir bir hastalık olduğu için, ileriye dönük randomize bir çalışma yoktur ve bilgilerin çoğu tek merkezin geriye dönük çalışma-larına ya da kadın meme kanseri (KMK) çalışmalarına dayanır. Bu makalede erkek meme kanserinde insidans, etiyoloji, klinik özellikler, tanı, tedavi, patoloji, sağkalım ve prognostik faktörler sunulmuştur. EMK ve KMK ara-sında tanı sırasında yaş, evre, histolojik tip, moleküler belirteçler, steroid hormon reseptör ekspresyonu bakı-mından farklar vardır. Modifiye radikal mastektomi halen standart tedavidir, adjuvan radyoterapi sıklıkla uygulanır ve tamoksifen kullanılır. Genel olarak, ileri yaş, büyük tümör boyutu, aksiller lenf nodu metastazı varlığı, ileri evre, yüksek grad, negatif hormon reseptör olması EMK’da kötü prognoz ile ilişkilidir.

🔖

Cite This Article

EROĞLU, A., ERSÖZ, Ş. (2010). Male breast cancer. Yeni Tıp Dergisi, Cilt: 27 - Sayı: 4, 202–207. https://ajindex.com/articles/338368

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Contractor KB, Kaur K, Rodrigues GS, Kulkarni DM, Singhal H. Male breast cancer: is the scenario changing. World J Surg Oncol 2008;6: 58
  2. Giordano SH, Cohen DS, Buzdar AU, Perkins GP, Hortobagyi GN. Breast carcinoma in men. A population-based study. Cancer 2004;101: 51-7
  3. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2009; 27 DOI: 10.1200/JCO.2009.23.8162
  4. Hill TD, Khamis HJ, Tyczynski JE, Berkel H. Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 2005;15: 773-80
  5. Anderson WF, Devesa SS. In situ male breast carcinoma in the Surveillance, Epidemiology, and End Results database of the National Cancer Institute. Cancer 2005;104: 1733-41
  6. Park S, Kim JH, Koo J, Park BW, Lee KS. Clinicopathological characeristics of male breast cancer. Yonsei Med J 2008;49: 978-86
  7. Sasco AJ, Lowenfels AB, Pasker-de Jong P. Review article: epidemiology of male breast cancer. A meta-analysis of published casecontrol studies and discussion of selected aetiological factors. Int J Cancer 1993;53: 538-49
  8. Amir H, Makyawa CK, Moshiro C, Kwesigabo G. Carcinoma of the male breast: a sexually transmitted disease? East Afr Med J 1996;73: 187-90
  9. Nggada HA, Yawe KDT, Abdulazeez J, Khalil MA. Breast cancer burden in Maiduguri. North Eastern Nigeria. Breast J 2008;14: 284-6
  10. Fentiman IS, Fourquet A, Hortobagyi GN. Male breast cancer. Lancet 2006;367: 595-604
  11. Anderson WF, Althuis MD, Brinton LA, Devesa SS. Is male breast Cancer similar or different than female breast cancer? Breast Cancer Res Treat 2004;83: 77-86
  12. Crew KD, Neugut AI, Wang X, Jacobson JS, Grann VR, Raptis G, et al. Racial disparities in treatment and survival of male breast cancer. J Clin Oncol 2007;25: 1089-98
  13. Gakwaya A, Kigula-Mugambe JB, Kavuma, Luwaga A, Fualal J, Jombwe J, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer 2008;99: 63-7
  14. Maalej M, Hentati D, Mesai T, Kochbati L, El May A, Mrad K, et al. Breast cancer in Tunisia in 2004: a comparative Clinical and epidemiological Study. Bull Cancer 2008;95: 5-9
  15. Meguerditchian A, Falardeau M, Martin G. Male breast carcinoma. Can J Surg 2002;45: 296-302
  16. Eser S. Kanser Kayıtçılığı ve Kanser Kayıt Merkezleri. Ed. Tuncer M. Türkiye’de Kanser Kontrolü. T.C. Sağlık Bakanlığı Kanserle Savaş Dairesi Başkanlığı Yayınları, 2007, 47-77. 1